Google Updates Policy to Allow CBD Advertising in Select Markets

Jan.11.2023
Google Updates Policy to Allow CBD Advertising in Select Markets
Google allows ads for marijuana and topical CBD products in California, Colorado and Puerto Rico, and FDA-approved drugs.

Google has updated its policies on "dangerous products and services, as well as healthcare and drugs," allowing advertisements for marijuana and topical CBD products to be promoted in California, Colorado, and Puerto Rico in the United States.


Google did not provide a clear explanation for why it is limiting ads in these three distinct markets.


The company stated that CBD advertisements for entertainment products are still subject to limitations, including "supplements, food additives and inhalants." Additionally, according to policy revisions, header ads on YouTube (owned by Google) appear at the top of the main homepage on all devices and do not apply to marijuana and CBD products.


Google also stated that drugs approved by the Food and Drug Administration (FDA) can now be advertised in these jurisdictions. This rule change will only benefit one manufacturer, Jazz Pharmaceuticals, whose high-CBD Epidiolex is the only product of its kind that the agency has approved to date. Epidiolex is used to treat severe seizures in children and was approved by the FDA in 2020.


These changes were announced at the end of the year and will take effect on January 20th. Advertisers can start applying for Google certification from that date and the application form will be released.


Google has announced that it has signed a contract with LegitScript, an internet and payment compliance company based in Portland, Oregon. LegitScript provides certification in high-risk industries and serves as a credential exchange for determining product advertising eligibility. Only products certified by LegitScript are permitted to be promoted on the Google platform.


According to Google, individuals seeking to advertise on the platform must provide their product samples or THC tests, and provide third-party analysis certificates to LegitScript for verification.


In an industry where contaminated, substandard, or illegal products are still prevalent, it is more important than ever to assure consumers that the CBD products they are purchasing have undergone proper scrutiny," said Scott Ross, CEO of LegitScript.


This internet giant appears to be unnerved by the prospect of continuing to use CBD products internally. Such products have received warnings from the FDA, as various studies have shown contamination by solvents and heavy metals among other impurities. Delta-8 THC derived from cannabis produced via synthetic processes has been implicated in the death of a child in Virginia last year.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

AIR Romania Manufacturing Facility Expected to Begin Operations in Q1 2027
AIR Romania Manufacturing Facility Expected to Begin Operations in Q1 2027
AIR Limited announced on May 7, 2026, that it plans to open a new manufacturing facility of approximately 70,000 square feet in Stefanesti, Bucharest North, Romania. The facility is expected to begin operations by the first quarter of 2027. AIR said that once fully operational, the facility is expected to support more than 150 jobs and be capable of producing more than 4,000 tons of flavored shisha molasses each year.
May.08 by 2FIRSTS.ai
France Bans Zyn and Other Nicotine Pouches, Violators Face Jail and Fines
France Bans Zyn and Other Nicotine Pouches, Violators Face Jail and Fines
France has officially banned nicotine pouches and other oral nicotine products, including Zyn. The new regulation classifies such products as “toxic substances” and imposes criminal penalties on their use, possession, purchase, and sale. Violators may face up to five years in prison and fines of up to €400,000 (approximately $436,600).
Regulations
May.25
Special Report | Russian Vape Compromise Faces First Hurdles
Special Report | Russian Vape Compromise Faces First Hurdles
Russia’s regional vape-ban model is facing early legal and political tests, as Perm Krai moves ahead before federal legislation is fully adopted. The case highlights uncertainty over regional authority, concerns from business groups about market fragmentation, and the risk that pressure against regional bans could revive calls for a stricter nationwide prohibition.
Industry Insight
May.28
FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02
PML Expands Its UK Smoke-Free Portfolio With LEVIA
PML Expands Its UK Smoke-Free Portfolio With LEVIA
Philip Morris Limited has launched LEVIA, a new range of zero-tobacco flavored nicotine sticks created for the IQOS ILUMA range. The product expands the company’s smoke-free portfolio in the UK and will initially be available in four variants, including Deep Mint and three capsule-based flavors. LEVIA has a recommended retail price of £5, or about $6.73, based on the European Central Bank’s April 28.
Apr.29 by 2FIRSTS.ai
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai